

Special Bulletin

For professional and facility providers

November 30, 2022

Authorization Changes Postponed for MSK Procedures, Molecular and Genomic Testing, and Radiation Services

We are postponing authorization changes we [announced](#) last month. That included preauthorization requirements for some musculoskeletal (MSK) procedures and interventional pain management, molecular and genomic testing, and radiation oncology services.

We have delayed the start date of this program, which will be managed by [eviCore](#), to late Q1 or early Q2 of 2023 to allow you more time to adjust to this change. For now, please continue to request authorization through your regular workflow.

Educational webinars will be offered sometime in advance of implementation to help you understand the new requirements and request process.

This information is issued on behalf of Highmark Blue Shield and its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association. Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in 21 counties in central Pennsylvania and 13 counties in northeastern New York. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania. Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware, and 8 counties in western New York. All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.